Monitoring procalcitonin in febrile neutropenia: What is its utility for initial diagnosis of infection and reassessment in persistent fever?

PLoS ONE

Volumn 6, Issue 4, 2011, Pages

  Robinson, James Owen ^a,b   Lamoth, Frédéric ^a   Bally, Frank ^a   Knaup, Marlies ^a   Calandra, Thierry ^a   Marchetti, Oscar ^a  

^a LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

^b ROYAL PERTH HOSPITAL   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

PROCALCITONIN; CALCITONIN; PROTEIN PRECURSOR;

ADULT; AGED; ARTICLE; BLOOD SAMPLING; CLINICAL EVALUATION; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DIAGNOSTIC TEST ACCURACY STUDY; DISEASE DURATION; FEBRILE NEUTROPENIA; FEMALE; HORMONE BLOOD LEVEL; HORMONE DETERMINATION; HUMAN; MAJOR CLINICAL STUDY; MALE; MYCOSIS; PATIENT MONITORING; SENSITIVITY AND SPECIFICITY; ADOLESCENT; BLOOD; FEVER; FOLLOW UP; INFECTION; KINETICS; MICROBIOLOGY; MIDDLE AGED; NEUTROPENIA; RECEIVER OPERATING CHARACTERISTIC;

STAPHYLOCOCCUS;

ADOLESCENT; ADULT; AGED; CALCITONIN; FEMALE; FEVER; FOLLOW-UP STUDIES; HUMANS; INFECTION; KINETICS; MALE; MIDDLE AGED; NEUTROPENIA; PROTEIN PRECURSORS; ROC CURVE; YOUNG ADULT;

EID: 79955552821     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0018886     Document Type: Article

References (39)

1. Hughes WT, Armstrong D, Bodey GP, Bow EJ, Brown AE, et al. (2002) 2002 guidelines for the use of antimicrobial agents in neutropenic patients with cancer. Clin Infect Dis 34: 730-751.
2. Scire CA, Cavagna L, Perotti C, Bruschi E, Caporali R, et al. (2006) Diagnostic value of procalcitonin measurement in febrile patients with systemic autoimmune diseases. Clin Exp Rheumatol 24: 123-128.
3. Muller B, Becker KL, Schachinger H, Rickenbacher PR, Huber PR, et al. (2000) Calcitonin precursors are reliable markers of sepsis in a medical intensive care unit. Crit Care Med 28: 977-983.
4. Kuse ER, Langefeld I, Jaeger K, Kulpmann WR, (2000) Procalcitonin in fever of unknown origin after liver transplantation: a variable to differentiate acute rejection from infection. Crit Care Med 28: 555-559.
5. Viallon A, Zeni F, Lambert C, Pozzetto B, Tardy B, et al. (1999) High sensitivity and specificity of serum procalcitonin levels in adults with bacterial meningitis. Clin Infect Dis 28: 1313-1316.
6. Gilbert DN, (2010) Use of plasma procalcitonin levels as an adjunct to clinical microbiology. J Clin Microbiol 48: 2325-2329.
7. Christ-Crain M, Jaccard-Stolz D, Bingisser R, Gencay MM, Huber PR, et al. (2004) Effect of procalcitonin-guided treatment on antibiotic use and outcome in lower respiratory tract infections: cluster-randomised, single-blinded intervention trial. Lancet 363: 600-607.
8. Christ-Crain M, Stolz D, Bingisser R, Muller C, Miedinger D, et al. (2006) Procalcitonin guidance of antibiotic therapy in community-acquired pneumonia: a randomized trial. Am J Respir Crit Care Med 174: 84-93.
9. Giamarellou H, Giamarellos-Bourboulis EJ, Repoussis P, Galani L, Anagnostopoulos N, et al. (2004) Potential use of procalcitonin as a diagnostic criterion in febrile neutropenia: experience from a multicentre study. Clin Microbiol Infect 10: 628-633.
10. Persson L, Engervall P, Magnuson A, Vikerfors T, Soderquist B, et al. (2004) Use of inflammatory markers for early detection of bacteraemia in patients with febrile neutropenia. Scand J Infect Dis 36: 365-371.
11. Ruokonen E, Nousiainen T, Pulkki K, Takala J, (1999) Procalcitonin concentrations in patients with neutropenic fever. Eur J Clin Microbiol Infect Dis 18: 283-285.
12. Giamarellos-Bourboulis EJ, Grecka P, Poulakou G, Anargyrou K, Katsilambros N, et al. (2001) Assessment of procalcitonin as a diagnostic marker of underlying infection in patients with febrile neutropenia. Clin Infect Dis 32: 1718-1725.
13. Pulliam PN, Attia MW, Cronan KM, (2001) C-reactive protein in febrile children 1 to 36 months of age with clinically undetectable serious bacterial infection. Pediatrics 108: 1275-1279.
14. Andreola B, Bressan S, Callegaro S, Liverani A, Plebani M, et al. (2007) Procalcitonin and C-reactive protein as diagnostic markers of severe bacterial infections in febrile infants and children in the emergency department. Pediatr Infect Dis J 26: 672-677.
15. The Immunocompromised Host Society (1990) The design, analysis, and reporting of clinical trials on the empirical antibiotic management of the neutropenic patient. Report of a consensus panel. J Infect Dis 161: 397-401.
16. JS G, WR J, TG E, TC H, JM H, Practice AICaAEPa, editor (1996) CDC definitions for nosocomial infections; St. Louis Olmsted RN pp. A1-A20.
17. Blijlevens N, Schwenkglenks M, Bacon P, D'Addio A, Einsele H, et al. (2008) Prospective oral mucositis audit: oral mucositis in patients receiving high-dose melphalan or BEAM conditioning chemotherapy-European Blood and Marrow Transplantation Mucositis Advisory Group. J Clin Oncol 26: 1519-1525.
18. Kern WV, Cometta A, De Bock R, Langenaeken J, Paesmans M, et al. (1999) Oral versus intravenous empirical antimicrobial therapy for fever in patients with granulocytopenia who are receiving cancer chemotherapy. International Antimicrobial Therapy Cooperative Group of the European Organization for Research and Treatment of Cancer. N Engl J Med 341: 312-318.
19. Cometta A, Kern WV, De Bock R, Paesmans M, Vandenbergh M, et al. (2003) Vancomycin versus placebo for treating persistent fever in patients with neutropenic cancer receiving piperacillin-tazobactam monotherapy. Clin Infect Dis 37: 382-389.
20. De Pauw B, Walsh TJ, Donnelly JP, Stevens DA, Edwards JE, et al. (2008) Revised definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) Consensus Group. Clin Infect Dis 46: 1813-1821.
21. Senn L, Robinson JO, Schmidt S, Knaup M, Asahi N, et al. (2008) 1,3-Beta-D-glucan antigenemia for early diagnosis of invasive fungal infections in neutropenic patients with acute leukemia. Clin Infect Dis 46: 878-885.
22. Institute. CaLSInstitute. CaLS, editor (2006) Methods for Dilution Antimicrobial Susceptibility Tests for Bacteria that Grow Aerobically-Seventh Edition: Approved Standard M7-A7.; USA.
23. Steinbach G, Rau B, Debard AL, Javourez JF, Bienvenu J, et al. (2004) Multicenter evaluation of a new immunoassay for procalcitonin measurement on the Kryptor System. Clin Chem Lab Med 42: 440-449.
24. Sakr Y, Sponholz C, Tuche F, Brunkhorst F, Reinhart K, (2008) The role of procalcitonin in febrile neutropenic patients: review of the literature. Infection 36: 396-407.
25. Engel A, Steinbach G, Kern P, Kern WV, (1999) Diagnostic value of procalcitonin serum levels in neutropenic patients with fever: comparison with interleukin-8. Scand J Infect Dis 31: 185-189.
26. Fleischhack G, Kambeck I, Cipic D, Hasan C, Bode U, (2000) Procalcitonin in paediatric cancer patients: its diagnostic relevance is superior to that of C-reactive protein, interleukin 6, interleukin 8, soluble interleukin 2 receptor and soluble tumour necrosis factor receptor II. Br J Haematol 111: 1093-1102.
27. Jimeno A, Garcia-Velasco A, del Val O, Gonzalez-Billalabeitia E, Hernando S, et al. (2004) Assessment of procalcitonin as a diagnostic and prognostic marker in patients with solid tumors and febrile neutropenia. Cancer 100: 2462-2469.
28. Schuttrumpf S, Binder L, Hagemann T, Berkovic D, Trumper L, et al. (2006) Utility of procalcitonin concentration in the evaluation of patients with malignant diseases and elevated C-reactive protein plasma concentrations. Clin Infect Dis 43: 468-473.
29. von Lilienfeld-Toal M, Dietrich MP, Glasmacher A, Lehmann L, Breig P, et al. (2004) Markers of bacteremia in febrile neutropenic patients with hematological malignancies: procalcitonin and IL-6 are more reliable than C-reactive protein. Eur J Clin Microbiol Infect Dis 23: 539-544.
30. Stryjewski GR, Nylen ES, Bell MJ, Snider RH, Becker KL, et al. (2005) Interleukin-6, interleukin-8, and a rapid and sensitive assay for calcitonin precursors for the determination of bacterial sepsis in febrile neutropenic children. Pediatr Crit Care Med 6: 129-135.
31. Beaune G, Bienvenu F, Pondarre C, Monneret G, Bienvenu J, et al. (1998) Serum procalcitonin rise is only slight in two cases of disseminated aspergillosis. Infection 26: 168-169.
32. Huber W, Schweigart U, Bottermann P, (1997) Failure of PCT to indicate severe fungal infection in two immunodeficient patients. Infection 25: 377-378.
33. Petrikkos GL, Christofilopoulou SA, Tentolouris NK, Charvalos EA, Kosmidis CJ, et al. (2005) Value of measuring serum procalcitonin, C-reactive protein, and mannan antigens to distinguish fungal from bacterial infections. Eur J Clin Microbiol Infect Dis 24: 272-275.
34. Christofilopoulou S, Charvalos E, Petrikkos G, (2002) Could procalcitonin be a predictive biological marker in systemic fungal infections? Study of 14 cases. Eur J Intern Med 13: 493-495.
35. Ortega M, Rovira M, Filella X, Almela M, Puig de la Bellacasa J, et al. (2004) Prospective evaluation of procalcitonin in adults with febrile neutropenia after haematopoietic stem cell transplantation. Br J Haematol 126: 372-376.
36. Ortega M, Rovira M, Filella X, Martinez JA, Almela M, et al. (2006) Prospective evaluation of procalcitonin in adults with non-neutropenic fever after allogeneic hematopoietic stem cell transplantation. Bone Marrow Transplant 37: 499-502.
37. Brunkhorst FM, Wegscheider K, Forycki ZF, Brunkhorst R, (2000) Procalcitonin for early diagnosis and differentiation of SIRS, sepsis, severe sepsis, and septic shock. Intensive Care Med 26 (Suppl 2): S148-152.
38. Sauer M, Tiede K, Fuchs D, Gruhn B, Berger D, et al. (2003) Procalcitonin, C-reactive protein, and endotoxin after bone marrow transplantation: identification of children at high risk of morbidity and mortality from sepsis. Bone Marrow Transplant 31: 1137-1142.
39. Svaldi M, Hirber J, Lanthaler AI, Mayr O, Faes S, et al. (2001) Procalcitonin-reduced sensitivity and specificity in heavily leucopenic and immunosuppressed patients. Br J Haematol 115: 53-57.